Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal. In the ...
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for treating cognitive symptoms in Parkinson’s disease, a condition currently ...
Yasir Gallero-Salas discusses quantifying alpha-synuclein spread and dopaminergic neuron loss in a model of Parkinson’s using ...
Nearly one million people in the U.S. are living with Parkinson’s disease (PD), and this number is expected to grow to 1.2 ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
People with Parkinson's who have taken part in drum lessons have seen a "tangible difference" in their mobility, according to ...
Exidavnemab is being developed as a potential disease-modifying treatment, aiming to halt or slow the progression of ...
Researchers have identified that G-quadruplexes promote harmful protein aggregation in neurodegenerative diseases. Blocking ...
Wearable devices once seemed futuristic for Parkinson’s disease. Today, tools like activity trackers, tremor gloves, and ...
When Denver artist Tim McKay was diagnosed with Parkinson’s disease last year, he made a quick decision: He would document ...
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by ...
BioArctic begins patient dosing in EXIST phase 2a study in Parkinson’s disease: Stockholm Saturday, December 7, 2024, 18:00 Hrs [IST] BioArctic AB (publ), a Swedish research-bas ...